# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mary Shelley (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI028-SYN
- Date: 2026-07-07
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rosamund Achterberg-Ilesanmi, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month MRI review after resection. **S**

## History of present illness

Ms. Shelley returns three months after resection of a grade 1 meningioma. The MRI five days ago shows no residual or recurrent tumor, the swelling has resolved, and there is only a small scar under the craniotomy. She finished occupational therapy, and her right hand now feels as it did years ago; she writes for two to three hours each morning. She has had no seizure for sixteen weeks. The irritability has faded, and she has seen the counselor six times, talking about the illness and about old losses she has never spoken of to a clinician. Dr. Ferreira-Lindgren saw her after the scan and found no reason, from the surgery, against driving. **S**

| Element | Detail |
|---|---|
| MRI | No residual or recurrent tumor; edema resolved |
| Seizures | None for sixteen weeks |
| Hand | Full strength; writing two to three hours a day |
| Mood | Irritability faded; six counselor sessions |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Negative | No seizures, aura, weakness, or headaches |
| Psychiatric | Negative | Mood better; no irritability; no thoughts of suicide |
| Constitutional | Negative | Energy back; weight stable |
| Integumentary | Negative | Scar healed |

4 systems reviewed. **S**

## Current medications

- Levetiracetam 500 mg oral tablet, one tablet by mouth twice a day **S**
- Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for headache or wound pain, no more than 3000 mg a day **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/74 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 57.6 kg; BMI 22.5 kg/m². All vital signs are synthetic.

PHQ-9: 6; GAD-7: 5. All results are synthetic.

## Change since baseline

- PHQ-9: 7 at baseline, 6 at this visit **S**
- GAD-7: 8 at baseline, 5 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well and cheerful |
| Neurological | Speech normal; grip, finger extension, and finger tapping equal on both sides; no drift; reflexes symmetric |
| Mental status | Mood "steadier"; affect bright; no thoughts of suicide |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Meningioma, CNS WHO grade 1, after resection** (D32.0). No residual or recurrent tumor at three months. **S**
   - Next MRI one year after surgery, then yearly to five years.
2. **Focal epilepsy on levetiracetam** (G40.109). Seizure-free for sixteen weeks with resolving side effects. PHQ-9 6 and GAD-7 5. Her state's seizure-free requirement of three months is met, and the neurosurgeon has cleared her to drive. **S**
   - Continue levetiracetam 500 mg twice a day; at one year after surgery, an EEG and a discussion of tapering.
   - She may drive again; no driving for at least three months after any seizure, and never after a missed dose with symptoms.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Surveillance MRI with gadolinium | Three months after resection, then yearly for five years, then every two years | Completed today | Five days ago: no residual or recurrent tumor; reviewed with her today |
| Self-management | Seizure diary, triggers (sleep loss, alcohol, missed doses), and seizure first aid | Every visit | Completed today | No seizures for sixteen weeks; no missed doses |
| Survey | PHQ-9, with a question about irritability on levetiracetam | Every visit while on levetiracetam and during cancer treatment | Completed today | 6, improving; irritability faded |
| Survey | GAD-7 | Every visit during the diagnostic and treatment phase | Completed today | 5, mild, done as the corrective action recorded at the last visit |
| Medication safety | Levetiracetam tolerability | Every visit | Completed today | Irritability resolved; no sleepiness or dizziness |
| Self-management | Driving | After the state's seizure-free period and surgical clearance | Completed today | Three months seizure-free and cleared by neurosurgery; may drive |
| Referral | Occupational therapy | Until hand function recovers | Completed today | Course finished; full function |

## Goal progress

- A diagnosis within two weeks, explained in plain words with the images and reports. Outcome by 2026-03-17: MRI and EEG within a week; diagnosis explained at two weeks with the images. **S**
- No further seizures. In progress; target 2027-04-07. **S**
- Full use of the right hand and return to writing every morning. In progress; target 2026-09-29. **S**
- Decide on treatment herself after hearing the options, benefits, and harms. Outcome by 2026-03-17: Chose resection after observation and radiosurgery were explained. **S**
- Mood and grief supported: PHQ-9 below 5 and a counselor available. In progress; target 2026-09-29. **S**

## Guideline basis

- EANO guideline on the diagnosis and management of meningiomas. Goldbrunner R, et al. Neuro Oncol 2021;23(11):1821-1834 (2021), European Association of Neuro-Oncology
- NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers, Version 2.2025 (2025), National Comprehensive Cancer Network
- Evidence-based guideline: Management of an unprovoked first seizure in adults. Krumholz A, et al. Neurology 2015;84(16):1705-1713 (2015), American Academy of Neurology and American Epilepsy Society
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (depression screening and PHQ-9 follow-up) (2026), Aether Forge

## Follow-up

- Review in about twelve weeks; counselor as she wishes; MRI one year after surgery. **S**
- Next scheduled visit 2026-09-29: six-month review after resection: seizures, mood, and writing. **S**
